Alignment Healthcare (ALHC) operates Medicare Advantage plans backed by a proprietary technology platform designed to serve high-need senior populations — and an executive's $550,000 stock sale has put the company back under the microscope just as its operational momentum hits a multi-year high.
At a Glance
- ALHC closed at $21.66 on June 21, 2026, up 3.1% on the day
- 52-week range: $13.05–$22.74; market cap: $4.52 billion
- Trailing-twelve-month revenue: $4.26 billion; TTM net income: $19.81 million
- Q1 2026 membership reached roughly 284,800, up 30.9% year over year
- The insider sale was executed under a pre-scheduled Rule 10b5-1 plan filed in March 2026
| Price | 21.66 USD |
|---|---|
| Day change | +0.66 (+3.1%) |
| 52-week range | 13.05 – 22.74 |
| Market cap | $4.52B |
| RSI (14) | 66.94 |
| Volume | 2,641,243 |
The Insider Transaction in Full
On June 18, 2026, Joseph S. Konowiecki, Alignment Healthcare's Executive Vice President of Corporate Affairs, sold 25,000 shares of common stock in an open-market transaction, according to an SEC Form 4 filing. The shares were sold at $22.00 each, putting the total transaction value at $550,000. After the sale, Konowiecki held 1,153,816 shares directly — worth roughly $25.22 million at the June 18 closing price of $21.86.
| Metric | Value |
|---|---|
| Shares sold | 25,000 |
| Transaction value (at $22.00) | $550,000 |
| Post-sale direct holdings | 1,153,816 shares |
| Post-sale direct holding value (at $21.86 close) | ~$25.22 million |
The 25,000 shares represent just over 2% of Konowiecki's pre-sale direct position. Critically, the sale was carried out under a Rule 10b5-1 trading plan adopted in March 2026 — a pre-arranged schedule that separates the decision to sell from any specific knowledge of company developments at the time of execution. That structure significantly limits the signal value of the transaction. An executive offloading a sliver of a very large position under a months-old plan reads differently than a discretionary sale timed to a specific catalyst.
Q1 2026: The Operational Story Behind the Stock
The more consequential data point isn't the insider filing — it's the first-quarter scorecard. Revenue jumped 33.3% year over year to $1.24 billion, and membership climbed 30.9% to approximately 284,800 members. Both figures reflect the kind of growth that attracts attention in a Medicare Advantage sector where scale is becoming a meaningful competitive dividing line.
Profitability metrics showed equal improvement. Alignment swung from a net loss in Q1 2025 to net income of $11.4 million in Q1 2026, and adjusted EBITDA grew nearly 88% to $37.9 million. Those aren't incremental gains — an 88% EBITDA jump alongside 33% revenue growth implies meaningful operating leverage in the company's cost structure.
Management followed up the quarter by raising the midpoint of full-year guidance across four metrics: membership, revenue, adjusted gross profit, and adjusted EBITDA. CEO John Kao described the quarter as evidence that Alignment can "grow with discipline," citing improvements in sales, clinical operations, and cost management. Raising guidance across the board after a strong Q1 is a meaningful signal, particularly in the Medicare Advantage space, where claims volatility can reverse apparent progress quickly.
What the Numbers Say
Valuation
At $21.66, ALHC trades near the top of its 52-week range of $13.05–$22.74, implying the stock has nearly doubled from its 12-month low. The $4.52 billion market cap sits against TTM revenue of $4.26 billion, which puts the price-to-sales ratio just above 1x — relatively modest for a company growing revenue at 33% annually. The source data does not provide a P/E ratio or EPS figure, and no dividend is paid, which is typical for a growth-oriented managed care company still in the early stages of consistent profitability. TTM net income of $19.81 million is thin relative to revenue, confirming the market is pricing Alignment on its growth trajectory rather than current earnings power.
Momentum (RSI)
The RSI sits at 66.94 — close to, but not yet at, the conventional 70-level overbought threshold. That reading is consistent with a stock gaining momentum without being stretched to the point where near-term mean reversion is statistically probable. The 3.1% single-session gain on June 21 contributed to that elevated reading, but the RSI alone doesn't confirm a reversal is imminent.
Bull Case vs. Bear-Case Risks
The bull case centers on the combination of accelerating membership growth, improving profitability, and a raised guidance framework. A 1-year price increase of 56.59% (measured through June 18) already reflects a significant re-rating, but if the company can demonstrate that its EBITDA margin expansion is durable rather than seasonal, the current multiple could prove undemanding.
Bear-case risks are real and specific to the Medicare Advantage market. Federal rate adjustments, changes in CMS risk-adjustment methodologies, and medical cost ratios that can spike unpredictably are structural challenges for every MA operator. Alignment's net income margin at the TTM level remains razor thin — $19.81 million on $4.26 billion in revenue — meaning a relatively modest claims headwind could erase profitability. Trading near the top of the 52-week range after a 56% run also leaves limited margin for guidance disappointment.
Frequently Asked Questions
What did the Alignment Healthcare insider sale involve?
EVP Joseph Konowiecki sold 25,000 shares at $22.00 per share on June 18, 2026, for total proceeds of $550,000. The transaction was executed under a Rule 10b5-1 plan adopted in March 2026, and he retained more than 1.15 million shares after the sale.
What is a Rule 10b5-1 trading plan?
A Rule 10b5-1 plan allows corporate insiders to schedule stock sales in advance under a predetermined formula or timetable, insulating transactions from accusations of trading on material non-public information. The plan must be established when the insider does not possess material non-public information.
How has Alignment Healthcare performed financially?
In Q1 2026, Alignment reported revenue of $1.24 billion (up 33.3% year over year) and net income of $11.4 million, reversing a year-ago loss. Full-year TTM revenue stands at $4.26 billion, with net income of $19.81 million.
Does Alignment Healthcare pay a dividend?
No dividend is currently associated with ALHC. The company is prioritizing growth in the Medicare Advantage market, which is consistent with the capital allocation approach typical of managed-care companies still scaling operations.
Where the Stock Sits Now
At $21.66 and pressing toward its 52-week high of $22.74, Alignment Healthcare is priced for continued execution. The insider sale itself carries little informational weight given its pre-planned structure and the size of Konowiecki's remaining position. What matters more is whether Q2 and the back half of 2026 confirm that Q1's membership growth and margin improvement weren't a one-quarter phenomenon. The guidance raise suggests management believes they will — but Medicare Advantage is an industry where conviction needs to be earned quarter by quarter.
